News
Why Is Insurance Firm Centene Stock Trading Higher On Thursday?
On Thursday, Centene Corporation (NYSE: CNC ) outlined its 2025 financial guidance .
For fiscal year 2025, the health insurance plan provider expects total revenues of $166.5 billion to $169.5 billion, compared to a consensus of $166.58 billion.
The guidance includes premium and service revenues of $154.0 billion to $156.0 billion. The company expects GAAP EPS of greater than $6.19, with adjusted EPS of greater than $7.25 compared to the consensus of $6.97.
Also Read: Donald Trump’s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
The company expects a Health benefits ratio (HBR) of 88.4% to 89.0%.
The insurer forecasts a 2025 selling, general, and administrative (SG&A) expense ratio of 8.1% to 8.7%, with an adjusted SG&A expense ratio of 8.1% to 8.7%.
The company reaffirms its 2024 premium and service revenues guidance if $143.5 billion to $144.5 billion, HBR guidance if 88.3% to 88.5%, and adjusted diluted EPS guidance of greater than $6.80 .
“Centene is a mission driven organization, dedicated to delivering high quality outcomes for more than 28 million members, many of whom are among the nation’s most medically complex and historically underserved populations. Over the last three years we improved our core operations and invested in the experience of our customers and providers, all while delivering on our financial commitments,” said Chief Executive Officer of Centene, Sarah London.
Full-year 2024 earnings will be reported on February 4, 2025.
Price Action: CNC stock is up 1.92% at $57.99 at the last check on Thursday.
Read Next:
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Why Is Insurance Firm Centene Stock Trading Higher On Thursday? originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.